CardioFocus completes $10 million financing:
This article was originally published in Clinica
CardioFocus has completed a second round of venture financing totalling $9.6 million. The financing was led by Oxford Bioscience Partners and Schroder Venture Life Sciences and included Guidant. The West Yarmouth, Massachusetts-based company's initial focus is the development of minimally invasive catheter ablation treatments for atrial fibrillation. CardioFocus's photonic ablation technology uses proprietary fibre optic catheters, LightStics, and a diode laser to give physicians an easy, flexible tool to make precise lesions, the company says. CardioFocus aims to begin clinical studies to use the technology for both percutaneous and surgical atrial fibrillation.